Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors

NCT04896697 is registered in ClinicalTrials.gov with Xilio Development, Inc. as lead sponsor.

NCT NCT04896697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04896697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors
Lead sponsor
Xilio Development, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
September 13, 2021
Completion date
May 18, 2026
Enrollment
125 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor